Cato Research Appoints Life Sciences Leader & Innovator to Executive Chairman
Durham, NC — Cato Research, LLC (CATO), a global provider of regulatory and clinical research services, announced today that its board of directors has appointed Mark Goldberg, M.D. to executive chairman, effective immediately. Dr. Goldberg brings to CATO more than 25 years of leadership and innovation experience in building premier life sciences businesses.
Dr. Goldberg recently served as president and COO of PAREXEL International Corporation. During his 21 years with the company, Dr. Goldberg leveraged his medical, technical and clinical research expertise to drive business results and build PAREXEL into one of the world’s leading biopharmaceutical service providers. He joined PAREXEL to start the company’s Medical Imaging business and later helped to found its technology subsidiary, Perceptive Informatics (later renamed PAREXEL Informatics). Dr. Goldberg began his career as a radiologist and clinical director of Teleradiology at Massachusetts General Hospital (MGH) after completing his postdoctoral training at Brigham & Women’s Hospital and MGH. He also helped found a telehealth spin-off from MGH. Dr. Goldberg currently serves on the board of Intensity Therapeutics, Inc., a clinical-stage biotechnology company.
“We’ve been searching for additional leadership talent to support our goal of building CATO into a leading clinical and regulatory services provider. Mark is the perfect fit with his wealth of experience in our industry,” said Lynda Sutton, co-founder and president, Cato Research. “I’m excited to have Mark on our team to help guide our growth and I look forward to working with him.”
Dr. Goldberg’s appointment follows CATO’s partnership in 2018 with strategic healthcare investors, Water Street Healthcare Partners and JLL Partners. The firms worked with CATO’s leadership team to recruit Dr. Goldberg to continue CATO’s expansion and support their collective goal of building CATO into a leading clinical and regulatory services provider.
“I’m honored to have the opportunity to join Cato Research, which has built an exceptional reputation for regulatory expertise and clinical excellence over the past three decades. This is a credit to the company’s leadership and employees. I look forward to working together to drive growth and expand CATO’s capability set to continue to deliver outstanding service and results on behalf of our customers,” said Dr. Goldberg.
About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost-effectiveness. For more information about Cato Research, visit cato.com.